EP3932421A4 - COMPOSITION FOR USE IN THE TREATMENT OF ALLERGIC DISEASES - Google Patents

COMPOSITION FOR USE IN THE TREATMENT OF ALLERGIC DISEASES Download PDF

Info

Publication number
EP3932421A4
EP3932421A4 EP20765494.8A EP20765494A EP3932421A4 EP 3932421 A4 EP3932421 A4 EP 3932421A4 EP 20765494 A EP20765494 A EP 20765494A EP 3932421 A4 EP3932421 A4 EP 3932421A4
Authority
EP
European Patent Office
Prior art keywords
treatment
composition
allergic diseases
allergic
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20765494.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3932421A1 (en
Inventor
Akira Shibuya
Kazumasa KANEMARU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tsukuba NUC
Original Assignee
University of Tsukuba NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tsukuba NUC filed Critical University of Tsukuba NUC
Publication of EP3932421A1 publication Critical patent/EP3932421A1/en
Publication of EP3932421A4 publication Critical patent/EP3932421A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
EP20765494.8A 2019-03-01 2020-02-28 COMPOSITION FOR USE IN THE TREATMENT OF ALLERGIC DISEASES Pending EP3932421A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019037353 2019-03-01
JP2019086233 2019-04-26
PCT/JP2020/008427 WO2020179700A1 (ja) 2019-03-01 2020-02-28 アレルギー疾患を処置することに用いるための組成物

Publications (2)

Publication Number Publication Date
EP3932421A1 EP3932421A1 (en) 2022-01-05
EP3932421A4 true EP3932421A4 (en) 2023-03-22

Family

ID=72338683

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20765494.8A Pending EP3932421A4 (en) 2019-03-01 2020-02-28 COMPOSITION FOR USE IN THE TREATMENT OF ALLERGIC DISEASES

Country Status (4)

Country Link
US (1) US20220153806A1 (https=)
EP (1) EP3932421A4 (https=)
JP (1) JP7546924B2 (https=)
WO (1) WO2020179700A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170106051A1 (en) * 2014-05-16 2017-04-20 Baylor Research Institute Methods and Compositions for Treating Autoimmune and Inflammatory Conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0805159D0 (en) * 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
US20100306863A1 (en) * 2007-07-23 2010-12-02 Bioxell S.P.A. Screening, therapy and diagnosis
US20130024961A1 (en) * 2009-12-01 2013-01-24 Christopher Burlak Methods of Modulating Thrombocytopenia and Modified Transgenic Pigs
CA2939931C (en) * 2014-02-28 2025-04-22 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170106051A1 (en) * 2014-05-16 2017-04-20 Baylor Research Institute Methods and Compositions for Treating Autoimmune and Inflammatory Conditions

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BANDINI GIULIA ET AL: "Protein O - and C -Glycosylation pathways in Toxoplasma gondii and Plasmodium falciparum", PARASITOLOGY, vol. 146, no. 14, 1 December 2019 (2019-12-01), GB, pages 1755 - 1766, XP093228976, ISSN: 0031-1820, DOI: 10.1017/S0031182019000040 *
COTE ROBERT ET AL: "CLEC receptors, endocytosis and calcium signaling", AIMS ALLERGY AND IMMUNOLOGY, vol. 1, no. 4, 1 January 2017 (2017-01-01), pages 207 - 231, XP055977892, ISSN: 2575-615X, DOI: 10.3934/Allergy.2017.4.207 *
DRINIC MIRJANA ET AL: "Toxoplasma gondii tachyzoite-extract acts as a potent immunomodulator against allergic sensitization and airway inflammation", SCIENTIFIC REPORTS, vol. 7, no. 1, 9 November 2017 (2017-11-09), US, XP093228974, ISSN: 2045-2322, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-017-15663-4> DOI: 10.1038/s41598-017-15663-4 *
D'SOUZA ANISHA A ET AL: "Asialoglycoprotein receptor mediated hepatocyte targeting - Strategies and applicat", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 203, 18 February 2015 (2015-02-18), pages 126 - 139, XP029149040, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2015.02.022 *
KANEMARU KAZUMASA ET AL: "Clec10a suppresses house dust mite-induced dermatitis (Mo-P3-9)", CYTOKINE, vol. 100, 1 December 2017 (2017-12-01), US, pages 90, XP055977584, ISSN: 1043-4666, Retrieved from the Internet <URL:https://www.sciencedirect.com/journal/cytokine/vol/100/suppl/C> *
KAZUMASA KANEMARU: "Clec10a regulates mite- induced dermatitis", vol. 4, no. 42, 6 December 2019 (2019-12-06), pages 1 - 14, XP009531092, ISSN: 2470-9468, Retrieved from the Internet <URL:https://syndication.highwire.org/content/doi/10.1126/sciimmunol.aax6908> DOI: 10.1126/SCIIMMUNOL.AAX6908 *
M. G. WAHRENBROCK: "Multiple Hepatic Receptors Cooperate to Eliminate Secretory Mucins Aberrantly Entering the Bloodstream: Are Circulating Cancer Mucins the "Tip of the Iceberg"?", CANCER RESEARCH, vol. 66, no. 4, 15 February 2006 (2006-02-15), pages 2433 - 2441, XP055065451, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-3851 *
See also references of WO2020179700A1 *

Also Published As

Publication number Publication date
WO2020179700A1 (ja) 2020-09-10
JP7546924B2 (ja) 2024-09-09
US20220153806A1 (en) 2022-05-19
JPWO2020179700A1 (https=) 2020-09-10
EP3932421A1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
MA54515A (fr) Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires
MA56387A (fr) Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3866781A4 (en) NOVEL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY DISEASES
MA47688A (fr) Compositions utiles dans le traitement de l&#39;amyotrophie spinale
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
IL263132B (en) Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
EP3632440A4 (en) USE OF LIGASTROZIN NITRONE DERIVATIVES FOR THE PREVENTION AND TREATMENT OF DIABETIC COMPLICATION DISEASES
EP3826666A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NRP2-ASSOCIATED DISEASES
MA55821A (fr) Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression
EP3976059A4 (en) TREATMENT OF ANGIOPOIETIN-LIKE 7 (ANGPTL7) ASSOCIATED DISEASES
EP3639833A4 (en) AGENTS FOR THE PREVENTION OR TREATMENT OF FAT RELATED DISEASES AND INFLAMMATION
EP4045036A4 (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
MA56392A (fr) Dérivés de 2h-indazole et leur utilisation dans le traitement de maladies
MA53193A (fr) Vidofludimus à utiliser dans le traitement ou la prévention de maladies virales
MA50233A (fr) Mic-1 et glp-1 destinés à être utilisés dans le traitement de l&#39;obésité
EP3866777A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP3523281A4 (en) AUTOPHAGIC RIVER AND PHOSPHOLIPASE D ACTIVATORS AND PROTEIN UNIT CLEANING INCLUDING DEW AND TREATMENT OF PROTEINOPATHIA
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
LT3586837T (lt) Kompozicijos, apimančios aminorūgštis, skirtos panaudoti kepenų ligų prevencijai ir gydymui
EP3768274A4 (en) COMPOSITION FOR USE IN THE TREATMENT OF DISEASES CAUSED BY LACK OF CALCIUM
EP3645120A4 (en) NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION
MA44762A (fr) Sémaglutide utilisé dans le traitement de maladies cardiovasculaires
EP4009982A4 (en) GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
PL4094754T3 (pl) Kompozycje do leczenia chorób związanych z agregacją białek i/lub zapobiegania takim chorobom

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211001

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/15 20060101ALI20221109BHEP

Ipc: A61K 38/16 20060101ALI20221109BHEP

Ipc: C12N 15/62 20060101ALI20221109BHEP

Ipc: C12N 5/07 20100101ALI20221109BHEP

Ipc: A61P 17/04 20060101ALI20221109BHEP

Ipc: A61P 17/00 20060101ALI20221109BHEP

Ipc: A61P 37/08 20060101ALI20221109BHEP

Ipc: A61P 27/16 20060101ALI20221109BHEP

Ipc: A61P 27/14 20060101ALI20221109BHEP

Ipc: A61P 27/02 20060101ALI20221109BHEP

Ipc: A61P 11/06 20060101ALI20221109BHEP

Ipc: A61P 11/02 20060101ALI20221109BHEP

Ipc: A61P 1/04 20060101ALI20221109BHEP

Ipc: A61K 45/00 20060101ALI20221109BHEP

Ipc: A61K 39/00 20060101AFI20221109BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20230216

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/15 20060101ALI20230210BHEP

Ipc: A61K 38/16 20060101ALI20230210BHEP

Ipc: C12N 15/62 20060101ALI20230210BHEP

Ipc: C12N 5/07 20100101ALI20230210BHEP

Ipc: A61P 17/04 20060101ALI20230210BHEP

Ipc: A61P 17/00 20060101ALI20230210BHEP

Ipc: A61P 37/08 20060101ALI20230210BHEP

Ipc: A61P 27/16 20060101ALI20230210BHEP

Ipc: A61P 27/14 20060101ALI20230210BHEP

Ipc: A61P 27/02 20060101ALI20230210BHEP

Ipc: A61P 11/06 20060101ALI20230210BHEP

Ipc: A61P 11/02 20060101ALI20230210BHEP

Ipc: A61P 1/04 20060101ALI20230210BHEP

Ipc: A61K 45/00 20060101ALI20230210BHEP

Ipc: A61K 39/00 20060101AFI20230210BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241204